AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
aceclofenac 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibufenac derivatives | 43 | 89796-99-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,IKBKB,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,STK33,TEK,TGFBR1,TTK | 36 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,DDR1,EPHB4,GRK2,MAP2K6,MAPK7,PDK4,SIK2,STK33 | 12 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.75 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.015 | % | Moderate | 0.75 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperreflexia | 82.83 | 34.99 | 18 | 899 | 6639 | 90620891 |
| Apraxia | 63.25 | 34.99 | 12 | 905 | 2250 | 90625280 |
| Perseveration | 55.46 | 34.99 | 8 | 909 | 277 | 90627253 |
| Vitreous detachment | 38.51 | 34.99 | 8 | 909 | 2370 | 90625160 |
| Myoclonus | 37.77 | 34.99 | 12 | 905 | 19156 | 90608374 |
| Drug interaction | 35.06 | 34.99 | 26 | 891 | 276427 | 90351103 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cutaneous symptom | 35.23 | 31.65 | 6 | 640 | 407 | 42620282 |
| Meningioma | 32.19 | 31.65 | 7 | 639 | 1720 | 42618969 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Amaurosis fugax | 77.20 | 31.99 | 16 | 2184 | 2374 | 110584725 |
| Hyperreflexia | 64.31 | 31.99 | 18 | 2182 | 9467 | 110577632 |
| Urinary tract disorder | 53.23 | 31.99 | 14 | 2186 | 5830 | 110581269 |
| Ocular discomfort | 52.44 | 31.99 | 15 | 2185 | 8518 | 110578581 |
| Apraxia | 49.76 | 31.99 | 12 | 2188 | 3528 | 110583571 |
| Haemorrhagic stroke | 49.39 | 31.99 | 16 | 2184 | 13773 | 110573326 |
| Perseveration | 46.81 | 31.99 | 8 | 2192 | 419 | 110586680 |
| Head discomfort | 40.64 | 31.99 | 15 | 2185 | 18985 | 110568114 |
| Altered state of consciousness | 38.41 | 31.99 | 20 | 2180 | 57606 | 110529493 |
| Haematuria | 34.14 | 31.99 | 21 | 2179 | 82984 | 110504115 |
| Generalised oedema | 33.67 | 31.99 | 15 | 2185 | 30689 | 110556410 |
| Eye pain | 32.28 | 31.99 | 17 | 2183 | 50082 | 110537017 |
| Vitreous detachment | 32.20 | 31.99 | 8 | 2192 | 2657 | 110584442 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AB16 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Acetic acid derivatives and related substances |
| ATC | M02AA25 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35544 | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Related Drugs by ATC class:
M01AB Acetic acid derivatives and related substances 16 drugs
M02AA Antiinflammatory preparations, non-steroids for topical use 28 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ankylosing spondylitis | indication | 9631008 | DOID:7147 |
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Backache | indication | 161891005 | |
| Osteoarthritis | indication | 396275006 | |
| Adhesive capsulitis of shoulder | indication | 399114005 | DOID:14188 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.37 | acidic |
| pKa2 | 1.38 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | DRUG LABEL | SCIENTIFIC LITERATURE | |||||
| Transthyretin | Secreted | Kd | 5.92 | CHEMBL | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 5.23 | DRUG MATRIX | |||||
| Aldose reductase | Enzyme | IC50 | 5.89 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| D01545 | KEGG_DRUG |
| 16689 | RXNORM |
| C0050403 | UMLSCUI |
| CHEBI:31159 | CHEBI |
| CHEMBL93645 | ChEMBL_ID |
| DB06736 | DRUGBANK_ID |
| C056498 | MESH_SUPPLEMENTAL_RECORD_UI |
| 71771 | PUBCHEM_CID |
| 5608 | INN_ID |
| RPK779R03H | UNII |
| 005957 | NDDF |
| 329923004 | SNOMEDCT_US |
| 391703003 | SNOMEDCT_US |
| RPK779R03H | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ClanzaCR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65697-450 | TABLET, FILM COATED | 200 mg | ORAL | Export only | 15 sections |